However, we observed no abnormalities in glucose metabolism parameters such as HbA1c and FPG with biweekly PEG-rhGH over the course of treatment, and no new cases of diabetes were reported, which are consistent with previous studies of long-acting GH formulations (12, 13). Here, GH1 is linked to diabetes mellitus.